Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma

BACKGROUND: Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. METHODS: We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantor, Evan, Wierzbicki, Kyle, Tarapore, Rohinton S, Ravi, Karthik, Thomas, Chase, Cartaxo, Rodrigo, Nand Yadav, Viveka, Ravindran, Ramya, Bruzek, Amy K, Wadden, Jack, John, Vishal, May Babila, Clarissa, Cummings, Jessica R, Rahman Kawakibi, Abed, Ji, Sunjong, Ramos, Johanna, Paul, Alyssa, Walling, Dustin, Leonard, Marcia, Robertson, Patricia, Franson, Andrea, Mody, Rajen, Garton, Hugh J L, Venneti, Sriram, Odia, Yazmin, Kline, Cassie, Vitanza, Nicholas A, Khatua, Soumen, Mueller, Sabine, Allen, Joshua E, Gardner, Sharon L, Koschmann, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Neuro-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340643/
https://www.ncbi.nlm.nih.gov/pubmed/35137228
http://dx.doi.org/10.1093/neuonc/noac030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340643/
https://www.ncbi.nlm.nih.gov/pubmed/35137228
http://dx.doi.org/10.1093/neuonc/noac030

Ejemplares similares